Intellia Therapeutics Inc (NTLA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Intellia Therapeutics Inc stock (NTLA) is currently trading at $13.26. Intellia Therapeutics Inc PS ratio (Price-to-Sales) is 22.41. Analyst consensus price target for NTLA is $25.29. WallStSmart rates NTLA as Sell.
- NTLA PE ratio analysis and historical PE chart
- NTLA PS ratio (Price-to-Sales) history and trend
- NTLA intrinsic value — DCF, Graham Number, EPV models
- NTLA stock price prediction 2025 2026 2027 2028 2029 2030
- NTLA fair value vs current price
- NTLA insider transactions and insider buying
- Is NTLA undervalued or overvalued?
- Intellia Therapeutics Inc financial analysis — revenue, earnings, cash flow
- NTLA Piotroski F-Score and Altman Z-Score
- NTLA analyst price target and Smart Rating
Intellia Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Intellia Therapeutics Inc (NTLA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Intellia Therapeutics Inc (NTLA) Key Strengths (2)
Revenue surging 78.80% year-over-year
85.62% of shares held by major funds and institutions
Supporting Valuation Data
Intellia Therapeutics Inc (NTLA) Areas to Watch (6)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Very expensive at 22.4x annual revenue
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
Intellia Therapeutics Inc (NTLA) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 78.80%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (22.41), Price/Book (2.26) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -53.50%, Operating Margin at -428.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -53.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 78.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NTLA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NTLA's Price-to-Sales ratio of 22.41x sits near its historical average of 23.17x (17th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 8% below its historical high of 24.25x set in Mar 2026, and 1% above its historical low of 22.28x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Intellia Therapeutics Inc (NTLA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Intellia Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 68M with 79% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 79% YoY, reaching 68M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.13 indicates a conservative balance sheet with 193M in cash.
Free cash flow is -69M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Intellia Therapeutics Inc maintain 79%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.02, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Intellia Therapeutics Inc.
Bottom Line
Intellia Therapeutics Inc is a high-conviction growth story with revenue accelerating at 79% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Intellia Therapeutics Inc(NTLA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.